Outlook on Emerging Markets (Lazard AM)

Summary

• The recovery in emerging markets equities that began in late March picked up steam in the fourth quarter thanks to COVID-19 vaccine breakthroughs and the US election outcome. The MSCI Emerging Markets Index outperformed global developed markets equities in 2020.
• Lazard AM expects that emerging markets economies will benefit further as the vaccine is distributed in developed markets during the first half of 2021 and in emerging markets later in 2021 and 2022; value companies, in particular, are poised to benefit from higher global growth.
• Despite a bumpy ride in 2020, emerging markets debt demonstrated its resilience: All segments of the asset class finished the year in positive territory, with corporate bonds leading.
• An expected recovery in global economic growth, solid fundamentals, and attractive valuations in the most cyclical parts of the asset class paint a bright picture for emerging markets debt in the year ahead. READ MORE

Similar Posts:

• 2018 Emerging Markets Outlook (Nikko Asset Management)
• 2018 Emerging Markets Outlook: The Next Leg of the Recovery (Mirae Asset)
• Emerging Market Debt Outlook 2018: A Global Rebalancing is Due (Vontobel)
• Morgan Stanley’s Shallett: Emerging Markets Beset By Risk & Rich Valuations (Citywire)
• What Makes Emerging Market Debt Tick? (CFA Institute)
• Are Emerging Markets Recoupling with Developed Markets? (II)
• Emerging Markets: How to Unlock the Next Wave of Returns (Amundi Asset Management)
• Three Reasons Why Investors Should Buy Frontier Market Stocks (The BlackRock Blog)
• Could Malaysian Equities See a Modest Recovery in 2020? (Franklin Templeton)
• Corporate Governance in Emerging Markets: Progress and Opportunity (Franklin Templeton)